



(12) Translation of
European patent specification

(11) NO/EP 3191511 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/18 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.02.26
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.09.20
(86)	European Application Nr.	16798122.4
(86)	European Filing Date	2016.11.14
(87)	The European Application's Publication Date	2017.07.19
(30)	Priority	2015.11.12, US, 201562254375 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Ablynx NV, Technologiepark 21, 9052 Ghent-Zwijnaarde, BE-Belgia
(72)	Inventor	BUYSE, Marie-Ange, Burgemeester Edmond Ronsestraat 23, 9820 Merelbeke, BE-Belgia BOUCNEAU, Joachim, Elsboslaan 41, 9840 De Pinte, BE-Belgia CASTEELS, Peter, Lindekouter 20, 9420 Erpe-Mere, BE-Belgia VAN HEEKE, Gino, Omloop 35 203, 9700 Eine, BE-Belgia
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	IMPROVED TNF BINDERS
(56)	References Cited:	WO-A1-2006/122787, WO-A2-2006/122786, WO-A2-2012/175741, MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732-745, XP002242391, ISSN: 0022-2836, DOI: 10.1006/JMBI.1996.0548, WO-A2-2015/173325, M. C. HOLLAND ET AL: "Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-[alpha] Receptor 1", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 33, no. 7, 6 July 2013 (2013-07-06), pages 1192-1203, XP055111245, ISSN: 0271-9142, DOI: 10.1007/s10875-013-9915-0 cited in the application, WO-A2-2013/024059

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Immunoglobulin enkelt variabelt domene (ISVD) som har aminosyresekvensen i
5 henhold til SEQ ID NO: 40.